Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed and Relapsed Burkitt and High-Grade B-Cell Lymphomas
NCT07724457Phase 3Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2026
- Primary completion
- Nov 2033
01
Overview
A Phase 3 trial of glofitamab in Burkitt lymphoma (BL), high grade B-cell lymphoma (HGBCL), sponsored by National Cancer Institute. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
Burkitt lymphoma (BL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT07724457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07724457.